IRIS - Res&Arch Institutional Research Information System - Research & Archive

SCHIAROLI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.283
AS - Asia 2.710
EU - Europa 1.951
SA - Sud America 490
AF - Africa 86
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.179
SG - Singapore 1.377
IT - Italia 479
IE - Irlanda 379
BR - Brasile 376
CN - Cina 374
HK - Hong Kong 353
RU - Federazione Russa 323
VN - Vietnam 182
DE - Germania 148
FR - Francia 146
GB - Regno Unito 96
BD - Bangladesh 87
KR - Corea 73
FI - Finlandia 71
UA - Ucraina 64
CA - Canada 58
SE - Svezia 51
IN - India 50
AT - Austria 40
AR - Argentina 38
EE - Estonia 36
TR - Turchia 31
JP - Giappone 25
PL - Polonia 23
NL - Olanda 22
ZA - Sudafrica 22
IQ - Iraq 21
MX - Messico 21
ID - Indonesia 19
VE - Venezuela 18
ES - Italia 16
PH - Filippine 16
UZ - Uzbekistan 16
PK - Pakistan 15
EC - Ecuador 14
BE - Belgio 13
CO - Colombia 12
CH - Svizzera 11
EG - Egitto 11
AE - Emirati Arabi Uniti 10
MA - Marocco 10
MY - Malesia 10
CL - Cile 9
KE - Kenya 9
PY - Paraguay 9
JO - Giordania 8
SA - Arabia Saudita 8
DZ - Algeria 7
LT - Lituania 7
BO - Bolivia 6
ET - Etiopia 6
PE - Perù 6
IL - Israele 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
GR - Grecia 4
HN - Honduras 4
JM - Giamaica 4
PA - Panama 4
TT - Trinidad e Tobago 4
AO - Angola 3
AU - Australia 3
CR - Costa Rica 3
IR - Iran 3
LB - Libano 3
LY - Libia 3
NI - Nicaragua 3
RO - Romania 3
SN - Senegal 3
SY - Repubblica araba siriana 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
GA - Gabon 2
KZ - Kazakistan 2
MD - Moldavia 2
NP - Nepal 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
TH - Thailandia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
BW - Botswana 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LU - Lussemburgo 1
LV - Lettonia 1
MG - Madagascar 1
Totale 8.515
Salva come PNG Salva come JPEG
Città #
Singapore 996
San Jose 500
Dublin 379
Hong Kong 352
Chandler 318
Ashburn 214
Perugia 185
San Mateo 169
Santa Clara 133
Boardman 125
Moscow 123
Altamura 116
Lauterbourg 98
Dearborn 94
Medford 83
Princeton 83
Lawrence 80
Beijing 75
New York 72
Seoul 72
Los Angeles 70
The Dalles 68
Munich 59
Ann Arbor 55
Wilmington 55
Ho Chi Minh City 52
Andover 51
Columbus 49
São Paulo 40
Dong Ket 39
Hanoi 34
Piscataway 33
Falls Church 30
Des Moines 25
Tokyo 25
Nuremberg 24
Helsinki 22
Redmond 22
Frankfurt am Main 21
Rio de Janeiro 21
Hefei 20
Montreal 19
Turku 18
Orem 17
Saint Petersburg 17
Amsterdam 16
Dallas 16
Florence 16
Vienna 16
Chicago 15
Houston 15
Rome 15
Norwalk 14
San Paolo di Civitate 14
Warsaw 14
Tashkent 13
Brussels 12
Jacksonville 12
Poplar 12
Toronto 12
Buffalo 11
London 11
Brooklyn 10
Chennai 10
Johannesburg 10
Manchester 10
Woodbridge 10
Ankara 9
Dhaka 9
Mexico City 9
Milan 9
Ottawa 9
Padova 9
San Francisco 9
Amman 8
Atlanta 8
Bastia umbra 8
Boston 8
Brasília 8
Denver 8
Falkenstein 8
Phoenix 8
Baghdad 7
Belo Horizonte 7
Curitiba 7
Naples 7
Redwood City 7
Shanghai 7
Addis Ababa 6
Bologna 6
Caracas 6
Council Bluffs 6
Espoo 6
Guangzhou 6
Haiphong 6
Izmir 6
Jakarta 6
Lappeenranta 6
Nairobi 6
Nanjing 6
Totale 5.678
Salva come PNG Salva come JPEG
Nome #
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients 134
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 132
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 122
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 120
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected 120
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 119
Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2 114
A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV patients on stable antiretroviral therapy 113
Partial achievement of the 90-90-90 UNAIDS target in a cohort of HIV infected patients from Central Italy 113
A first update on mapping the human genetic architecture of COVID-19 110
Effects of antiretroviral therapy on lipid and immunovirological profile: Focus on proprotein convertase subtilisin/kexin 9 110
Mapping the human genetic architecture of COVID-19 107
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 105
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 105
Biochemical markers of bone turnover and calcium dietary intake evaluation in HIV-infected patients 103
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa 103
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 102
Low brachial artery flow-mediated dilation predicts worse prognosis in hospitalized patients with covid-19 101
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 101
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 99
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 99
Predictive risk factors for worse outcomes in COVID-19 patients with different clinical features at baseline 99
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 98
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 98
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 97
Seroprevalence of anti-SARS-CoV2 antibodies in umbrian persons living with HIV 96
Role of nucleocapsid protein antigen detection for safe end of isolation of sars-cov-2 infected patients with long persistence of viral rna in respiratory samples 96
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 95
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 95
An explainable model of host genetic interactions linked to COVID-19 severity 93
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 93
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism 92
The association between neutrophil to lymphocyte ratio and endothelial dysfunction in people living with HIV on stable antiretroviral therapy 91
Reactivation of hepatitis B virus replication due to cytotoxic therapy:a five-year prospective study 90
Percutaneous vertebroplasty improves pain control and quality of life in patients suffering from back pain: A single center experience 90
Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters 90
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 89
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 88
Genetic mechanisms of critical illness in COVID-19 88
Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) 86
BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV 86
Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy. 86
Bone-turnover markers in white HIV-infected patiens treated with or without TDF-containg regimens 86
The HIV Matrix Protein p17 promotes the Activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 85
Prevalence of smoking and nicotine dependence in HIV patients, the project STOPS HIV from Italy 85
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 85
Early treatment with bamlanivimab alone does not prevent COVID-19 hospitalization and its post-acute sequelae. A real experience in Umbria, Italy 85
Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital. 84
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 84
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients 84
Whole-genome sequencing reveals host factors underlying critical COVID-19 83
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 81
Lingual tubercolosis: a rare disease in western countries 81
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 81
Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir 79
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 77
Nelfinavir: An Old Ally in the COVID-19 Fight? 77
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial 77
Is the rate of virological failure to cART continuing to decline in recent calendar years? 77
Diagnosis of Nocardia paucivorans central nervous system infection by DNA sequencing from paraffin-embedded tissue 76
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? 75
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 74
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 74
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 73
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: A cross-sectional analysis 72
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 70
Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry 70
Meningitis with cranial polyneuritis and cavernous sinus thrombosis by Borrelia crocidurae: First autochthonous case in Europe 69
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 69
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 68
Protective role of a tmprss2 variant on severe covid-19 outcome in young males and elderly women 68
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 67
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 66
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 66
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report 65
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level 65
HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes 64
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 63
Management of Meningitis Caused by Multi Drug-Resistant Acinetobacter Baumannii: Clinical, Microbiological and Pharmacokinetic Results in a Patient Treated with Colistin Methanesulfonate 62
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting 62
Elevated serum uric acid levels are associated with endothelial dysfunction in HIV patients receiving highly-active antiretroviral therapy 61
Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm 61
The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication 60
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 60
Gangrenous Chickenpox with Atypical Clinical and Histopathological Findings. 60
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients 60
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 60
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 59
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART 58
Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry 58
Transgender people living with HIV: characteristics and comparison to homosexual and heterosexual cisgender patients in two Italian teaching hospitals 56
Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy 55
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 55
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 55
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study 54
Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach 53
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 52
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 51
Clinical and molecular characterization of COVID-19 hospitalized patients 50
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 49
Totale 8.224
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.656
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.656
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202140 0 0 0 0 0 0 0 0 0 0 0 40
2021/2022663 29 120 5 12 27 17 14 179 30 47 94 89
2022/20231.260 88 269 17 109 92 106 9 39 469 0 36 26
2023/2024512 27 71 20 8 5 3 134 4 28 29 102 81
2024/20251.837 26 132 65 63 212 85 160 91 415 132 288 168
2025/20263.825 247 225 241 471 469 304 690 208 482 268 143 77
Totale 8.850